- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03551093
THE IMPACT- 24M TRIAL (IMPlant Augmenting Cerebral Blood Flow in Mild Strokes Trial 24 Hours From Stroke Onset) (ImpACT-24M)
A Multicenter, Single Arm Trial to Assess Safety and Signal of Efficacy of the Ischemic Stroke System (ISS), as an Adjunct to Standard of Care in Subjects With Mild Acute Ischemic Stroke
Study Population:
Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from onset.
Study objectives:
- Identify the personal stimulation level for each patient based on physiological biomarkers
- Identify improvement in stroke symptoms during ISS treatment at the personal stimulation level
Study Overview
Detailed Description
A Multicenter, Single Arm Trial to Assess Safety and Signal of Efficacy of the Ischemic Stroke System (ISS), as an Adjunct to Standard of Care in Subjects with Mild Acute Ischemic Stroke
Study Duration:
The expected total duration of the study for each subject is up to 10 days as follows:
Enrollment: up to 24 hours Treatment: Implantation, 5 Days of SPG stimulation and Standard of care Final Visit: 7 days after enrollment
Study Population:
Subjects with Mild Acute Ischemic Stroke in the anterior circulation within 24 hours from onset.
Study Objectives:
- Identify the personal stimulation level for each patient based on physiological biomarkers
- Identify improvement in stroke symptoms during ISS treatment at the personal stimulation level
Study Design:
This will be a multi-center, adjunctive to Standard of Care, single arm study, which includes the following steps:
- Screening (day 1)
- Implantation (day 1)
- Treatment and symptom assessment (days 1-5)
- Device Positioning and Removal (day 5)
- Discharge/Final Visit (day 7-10)
Outcome Measures:
Primary Outcome Measures:
- The difference in NIHSS between baseline and Day 7 vs. Historical Controls
- % of patients with improvement in stroke symptoms (motor and/or sensory deficits) during stimulation
Additional Efficacy Outcome Measures:
- Existence of physiologic surrogates of the Personal Stimulation Level
- Improvement in stroke symptoms (motor and/or sensory deficits)
Safety Outcome Measures:
Comparative 7-day safety data between the ISS stimulation group of this study and of the ImpACT-24B study:
- Incidence of Serious Adverse Events
- Implantation Complications
- Stimulation-related Adverse Events
- 7-day mortality
- Neurological deterioration
- Symptomatic intracranial hemorrhage (sICH)
Implantation Accuracy Outcome Measures:
1. % of procedures with positive indication of reaching the sphenopalatine fossa
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kutaisi, Georgia, 4600
- Kutaisi Referral Hospital
-
Rustavi, Georgia, 3700
- Rustavi Central Hospital
-
Tbilisi, Georgia, 0141
- First University Clinic
-
Zugdidi, Georgia, 2100
- Zugdidi Referral Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: ≥ 18 years and ≤ 80 years
- Clinical diagnosis of anterior circulation stroke
- Baseline NIHSS ≥ 1 and ≤ 6 or lacunar stroke of any severity
- Motor and/or sensory deficits
- Ability to initiate treatment within 24 hours from stroke onset
Signed informed consent from patient him/herself or legally authorized representative if applicable.
Exclusion Criteria:
- Neuro-imaging evidence of any intracranial hemorrhage or hemorrhagic transformation of brain infarct or other significant abnormality (e.g. tumor, abscess, suspect for subarachnoid hemorrhage).
- Massive stroke, defined as acute parenchymal lesion with effacement of cerebral sulci in over 2/3 of the MCA territory.
- Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or Posterior Cerebral Artery territories), including but not limited to brain-stem findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical blindness.
- NIHSS level of consciousness score ≥ 2.
- Inability to communicate fluently and express symptoms
- Previous motor and/or sensory deficits that will eliminate the ability to identify the response to SPG stimulation
- Patients with bleeding propensity and/or one of the following: INR > 1.8, prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count < 75×109/L.
- Known cerebral arteriovenous malformation, cerebral aneurysm.
- Seizure at onset.
- Blood glucose concentration < 60 mg/dL.
- Clinical suspicion of septic embolus.
- Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg), demonstrated on each of three repeated measurements taken within one hour regardless of whether or not the patient is taking antihypertensive medications.
- Serious systemic infection.
- Women known to be pregnant or having a positive or indeterminate pregnancy test.
- Patients with other implanted neural stimulator/ electronic devices (pacemakers).
- History of SPG ablation ipsilateral to the stroke side.
- Any condition in the oral cavity that prevents implantation of the INS, such as patient is intubated, orthodontics or non-hygienic condition.
- Life expectancy < 1 year from causes other than stroke.
- Participating in any other therapeutic investigational trial within the last 30 days.
- Known sensitivity to any medications to be used during study.
- Subjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include: cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute ischemic stroke), or neoplastic diseases, as determined by medical history, physical examination, laboratory tests, or ECG.
- Subjects who, in the judgment of the investigator, are likely to be non- compliant or uncooperative during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Population
The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
|
The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NIHSS Assessment
Time Frame: Day 7
|
The difference in NIHSS between baseline and Day 7 vs.
Historical Controls (the historical controls are patients in the control arm in the NINDS trial)
|
Day 7
|
% of patients with improvement in stroke symptoms during stimulation
Time Frame: Day 2-5
|
Assessment of improvement in stroke symptoms (motor and/or sensory deficits) before and during stimulation at the Personal Stimulation Level, using a hand dynamometer (Baseline Hydraulic Hand Dynamometers, Fabrication Enterprises Inc, White Plains NY, USA).
|
Day 2-5
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased blood flow in Common Carotid Doppler
Time Frame: Day 1-5
|
Increased blood flow in Common Carotid Doppler (if available) during stimulation at the Personal Stimulation Level (physiologic surrogates).
|
Day 1-5
|
Existence of unilateral lacrimation, nasal secretion, and/or facial redness
Time Frame: Day 1-5
|
Unilateral lacrimation, nasal secretion, and/or facial redness (on the stimulation side) during stimulation at the Personal Stimulation Level (physiologic surrogates).
|
Day 1-5
|
Improvement in stroke symptoms
Time Frame: Day 2-5
|
Assessment of improvement in stroke symptoms (motor and/or sensory deficits) before and during stimulation at the Personal Stimulation Level, using a hand dynamometer (Baseline Hydraulic Hand Dynamometers, Fabrication Enterprises Inc, White Plains NY, USA).
The investigator will measure the grasp force and pincer force before and during stimulation in the affected and non-affected sides.
|
Day 2-5
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP0050613
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on ISS SPG stimulation
-
BrainsGateUnknown
-
BrainsGateCompletedIschemic StrokeIsrael, Hong Kong, Denmark, Spain, France, Finland, United States, Serbia, Czechia, Italy, Portugal, Germany, Georgia, Poland, Canada, North Macedonia, Slovakia, Ukraine
-
BrainsGateCompletedIschemic Stricture of IntestineIndia
-
The Cleveland ClinicAutonomic Technologies, Inc.CompletedMigraine HeadacheUnited States
-
NYU Langone HealthCompletedIpsilateral Shoulder PainUnited States
-
Raydiant Oximetry, Inc.Terminated
-
Laval UniversityGlaxoSmithKline; Canadian Lung AssociationTerminated
-
Columbia UniversityUniversity of Colorado, Denver; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsRecruiting
-
Nexilis AGTerminatedOsteoporotic Fracture of VertebraAustria
-
Dynavax Technologies CorporationTerminated